Month: April 2020

NORDIC ID OYJYHTIÖTIEDOTE 16.04.2020 KELLO 08:00Nordic ID Oyj:n hallitus ilmoittaa, että yhtiön toimitusjohtaja Juha Reima on irtisanoutunut tehtävästään henkilökohtaisista syistä 15.4.2020. Reima jatkaa kuitenkin yhtiön palveluksessa vastuullaan käynnissä olevien rahoitusneuvottelujen loppuunsaattaminen.Yhtiön hallitus on nimennyt Nordic ID Oyj:n uudeksi toimitusjohtajaksi Ratkaisupalveluliiketoiminnan johtajan Juuso Lehmuskosken 16.4.2020 alkaen.Hallituksen puheenjohtaja Jorma Lalla kommentoi:”Minä ja koko hallitus haluamme kiittää Juhaa hänen sitoutumisestaan yhtiön liiketoiminnan transformaatioon laitevalmistajasta palveluntarjoajaksi sekä hänen työstään toimitusjohtajan tehtävässä. Olen iloinen, että osaava seuraajaehdokas löytyi talon sisältä.”Lisätietoja:Hallituksen puheenjohtaja Jorma Lalla, puh. 0400 525 986Hyväksytty neuvonantaja:...

PRESS RELEASERegulated Information16 April 2020, 7:00am, Antwerp (Berchem), Belgium: VGP NV (‘VGP’ or ‘the Group’), a leading European provider of high-quality logistics and semi-industrial real estate, today published a trading update for the first quarter of 2020:Impact of Covid-19Our primary focus is the health, safety and well-being of our employees and partnersThe VGP team is operational, mostly working from home, with full access to systems. Where allowed, our construction sites are fully operationalUntil now the impact on rental payments is very limited: nearly all due payments were received on time. Some selective reprofiling discussions ongoing but it is probably too early to assess the whole impact of the respective measures taken to contain the spread of the virus on our tenantsAll pre-let development projects have now been...

PERSBERICHTGereguleerde Informatie16 april 2020, 7u00, Antwerpen (Berchem), België: VGP NV (‘VGP’ of ‘de Groep’), een toonaangevende Europese ontwikkelaar, manager en eigenaar van kwalitatief hoogstaand logistiek en semi-industrieel vastgoed, heeft vandaag een trading update gepubliceerd voor het eerste kwartaal van 2020:Gevolgen van Covid-19:Onze primaire focus is de gezondheid, de veiligheid en het welzijn van onze medewerkers en partnersHet VGP-team is operationeel, grotendeels thuiswerkend, met volledige toegang tot onze systemen. Waar toegestaan zijn onze bouwplaatsen volledig operationeelTot nu toe is de impact op de huurbetalingen zeer beperkt: bijna alle verschuldigde betalingen werden op tijd ontvangen. Er lopen een beperkt aantal besprekingen ter herprofilering, maar het is waarschijnlijk te vroeg om de hele impact van de respectievelijke...

Company announcement 5/2020 (16 April 2020)European Energy A/S’ Annual Report for 2019 is now available. It is attached to this company announcement and available on www.europeanenergy.dk under “Investors”.The European Energy Group delivered an impressive result for 2019, as the Group’s EBITDA totalled EUR 44.3 million (+32%) and the profit before tax was EUR 37.4 million (+44%), this compared to an EBITDA of EUR 33.6 million and profit before tax of EUR 25.9 million in 2018.European Energy experienced a continuous growth in the development pipeline of projects along with projects that are ready-to-build or under construction.European Energy maintains its positive outlook for 2020. European Energy continues to see interest for its energy parks among institutional investors despite the COVID-19 health crisis, while the...

SOUTH SAN FRANCISCO, Calif., April 16, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced the pricing of its previously announced underwritten public offering and is selling 5,000,000 shares of its common stock at a price to the public of $6.25 per share. Gross proceeds to Calithera from the offering are expected to be $31,250,000, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock are being offered by Calithera. In addition, Calithera has granted the underwriter a 30-day option to purchase up to 750,000 of additional shares of common stock at the public offering...

TORONTO, April 15, 2020 (GLOBE NEWSWIRE) — Wayland Group Corp. (CSE:WAYL) (“Wayland” or the “Company”) today announced that it has entered into a definitive transaction agreement with respect to its previously announced transaction with Ring International Holding AG (“Ring”) pursuant to which it will sell all of the issued and outstanding shares of Wayland’s subsidiary, Maricann Inc. (“Maricann”), and certain other property of Wayland and its affiliates to an affiliate of Ring for a purchase price of up to CAD $12,400,000 (the “Transaction”).As previously announced, Wayland will seek an approval and vesting order in respect of the Transaction at the hearing currently scheduled for April 21, 2020 before the Ontario Superior Court of Justice (Commercial List) (the “Court”) in the Companies’ Creditors Arrangement Act proceedings (the...

INNOVIA APM 100 system to be equipped with Bombardier’s state-of-the-art CITYFLO 650 signalling technology to extend its lifecycle by at least ten years Contract continues more than 25 years of cooperation with Fraport and the successful transportation of millions of passengers – around the clock and with a reliability of almost 100 per centBERLIN, April 16, 2020 (GLOBE NEWSWIRE) —Note to editors: To view the photos associated with this press release, please visit the following links: https://www.globenewswire.com/NewsRoom/AttachmentNg/0abfce1d-8d4b-4f2d-bb3e-ae70c50cb355https://www.globenewswire.com/NewsRoom/AttachmentNg/c321972b-690b-4d72-b7fb-0afc3e34340a Global mobility solution provider Bombardier Transportation has signed a ten-year contract with Fraport AG to continue operating and maintaining the BOMBARDIER INNOVIA...

INNOVIA APM 100-System wird mit Bombardiers hochmoderner CITYFLO 650-Signaltechnik ausgestattet, um dessen Lebenszyklus um mindestens zehn Jahre zu verlängernFortsetzung der über 25jährigen Zusammenarbeit mit Fraport und der erfolgreichen Beförderung von Millionen von Reisenden – rund um die Uhr und mit einer Zuverlässigkeit von fast 100 ProzentBERLIN, April 16, 2020 (GLOBE NEWSWIRE) —Fotos zu dieser Pressemitteilung finden Sie unter den folgenden Links: https://www.globenewswire.com/NewsRoom/AttachmentNg/0abfce1d-8d4b-4f2d-bb3e-ae70c50cb355https://www.globenewswire.com/NewsRoom/AttachmentNg/c321972b-690b-4d72-b7fb-0afc3e34340aBombardier Transportation, Anbieter von globalen Mobilitätslösungen, hat mit der Fraport AG einen Zehn-Jahres-Vertrag über den Betrieb und die Wartung des Peoplemover-Systems BOMBARDIER INNOVIA APM 100...

Charlotte, NC, April 15, 2020 (GLOBE NEWSWIRE) — Ballantyne Strong, Inc. (NYSE American: BTN) (“Ballantyne Strong” or the “Company”) today announced that Mark Roberson has been promoted to Chief Executive Officer and that Todd Major has been appointed as Chief Financial Officer. Kyle Cerminara will continue to lead the Company’s Board of Directors in the role of Non-Executive Chairman.“These well-deserved promotions are the result of the Board’s planning initiatives to strengthen the management team at Ballantyne Strong,” said Kyle Cerminara, Chairman of the Board. “Mark has led the turnaround in our financial and operational performance over the past 18 months. Todd has stepped in to lead our financial organization over the past year, bringing tremendous financial expertise and leadership to the Company. These changes reflect the...

SYDNEY, Australia, April 16, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing partner for its preclinical candidate, IMP761, has made significant progress in the cell line development for the product candidate which is an immunosuppressive agonist antibody to LAG-3.Using its STEP®-mAb technology, Batavia Biosciences has developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761. The Company will now complete the preparations for the Good Manufacturing Practice (GMP) process compliance development phase, ahead of clinical testing of the compound in autoimmune disease.Immutep reported encouraging preclinical results from its studies of IMP761 in early 2019. The in...